The TCS top management is moving fast to weather the subprime storm. Its focusing on order from Europe and on Tuesday they managed a multi million dollar outsourcing contract from a Switzerland based $33 billion healthcare major Roche. Deal could be in the range of $30-50 million and span over 3-5 years.
It is a very significant deal for us. For the first time we are getting into core drug development moving up the value chain. It is a multi million dollar multi year contract, said J Rajagopal, Executive VP & Global Head - Life Sciences & Healthcare, TCS.
Among technology firms, Patni''s buyout of Taco and igate expansion too has been in pharma verticals.
TCS currently earns five per cent of its revenue from the pharma industry. But is keen to ramp up its exposure in what''s core drug development software. With an aim to aid research, this space to move up the value chain and is aiming to bag a few more deals.
We are pitching in for similar deals and going forward I can''t quote numbers but will increase our business from the vertical, said Rajagopal.
While driving volumes is one part of the story, TCS is thinking ahead of possible future growth areas for the company. That may add to margins by moving into previously unchartered territory like drug development, a strategy that has so far done well for the company.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment